Inventor · disambiguated record
Martin Schmidt
Also filed as: SCHMIDT MARTIN · SCHMIDT MARTIN U · SCHMIDT MARTIN ULRICH
28 granted patents·15 pending applications·185 citations·filing 1994–2025
96Inventor score
Top patents by PatentIndex Score
43 records- 0190US8323651B2Antibodies to receptor of advanced glycation end products (RAGE) and uses thereofGU JIJIE·Filed 2009·Granted Dec 4, 2012·29 cites·12 claims
- 0287US9828381B2Substituted pyrazolopyrimidines and method of useABBVIE DEUTSCHLAND·Filed 2016·Granted Nov 28, 2017·3 cites·14 claims
- 0387US6504045B2Crystal polymorphs of a yellow disazo colorant, and their preparationCLARIANT GMBH·Filed 2001·Granted Jan 7, 2003·23 cites·18 claims
- 0484US10556914B2Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of useABBVIE INC·Filed 2019·Granted Feb 11, 2020·4 cites·16 claims
- 0583US9605069B2Antibodies against the RGM a protein and uses thereofABBVIE DEUTSCHLAND·Filed 2015·Granted Mar 28, 2017·3 cites·11 claims
- 0680US8962803B2Antibodies against the RGM A protein and uses thereofMUELLER BERNHARD K·Filed 2009·Granted Feb 24, 2015·3 cites·69 claims
- 0780US6683055B1Low molecular weight inhibitors of complement proteasesBASF AG·Filed 2000·Granted Jan 27, 2004·17 cites·16 claims
- 0879US6602342B2Crystal polymorphs of C.I. Pigment Yellow 191 and their preparationCLARIANT GMBH·Filed 2001·Granted Aug 5, 2003·15 cites·15 claims
- 0979US6060300AThrombin muteins as antidotes for thrombin inhibitorsBASF AG·Filed 1997·Granted May 9, 2000·41 cites·12 claims
- 1075US7491729B23-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereofABBOTT GMBH & CO KG·Filed 2003·Granted Feb 17, 2009·9 cites·18 claims
- 1174US7824488B2Pigment composition based on C.I. pigment yellow 191CLARIANT FINANCE BVI LTD·Filed 2008·Granted Nov 2, 2010·3 cites·12 claims
- 1274US7709614B2Crystalline modifications of C.I. pigment yellow 181 and associated production methodCLARIANT PRODUKTE DEUTSCHLAND·Filed 2005·Granted May 4, 2010·3 cites·21 claims
- 1372US9291621B2AGER-peptides and use thereofHAHN ALFRED·Filed 2006·Granted Mar 22, 2016·2 cites·9 claims
- 1472US7307170B2Epindolidione pigmentsCLARIANT FINANCE BVI LTD·Filed 2002·Granted Dec 11, 2007·6 cites·10 claims
- 1571US2021230260A1Antibodies against the rgm a protein and uses thereofABBVIE DEUTSCHLAND·Filed 2020·Application pending·0 cites
- 1671US2022018855A1RGMa Fragment Based Diagnostic AssayABBVIE DEUTSCHLAND·Filed 2021·Application pending·0 cites
- 1770US7416596B2Use of a pigment composition comprising mixed crystals based on CI pigment yellow 74CLARIANT PRODUKTE DEUTSCHLAND·Filed 2005·Granted Aug 26, 2008·2 cites·10 claims
- 1869US9394363B2Antibodies to receptor of advanced glycation end products (RAGE) and uses thereofABBVIE DEUTSCHLAND·Filed 2012·Granted Jul 19, 2016·1 cites·10 claims
- 1965US7906120B2Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR)ABBOTT LAB·Filed 2007·Granted Mar 15, 2011·0 cites·21 claims
- 2063US9255146B2Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereofABBVIE DEUTSCHLAND·Filed 2013·Granted Feb 9, 2016·0 cites·6 claims
- 2163US2019233510A1NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE NOGO-66 RECEPTOR (NgR) AND USES THEREOFABBVIE DEUTSCHLAND·Filed 2018·Application pending·0 cites
- 2261US10040852B2Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereofABBVIE DEUTSCHLAND·Filed 2016·Granted Aug 7, 2018·0 cites·14 claims
- 2360US2018162933A1Antibodies against the rgm a protein and uses thereofABBVIE DEUTSCHLAND·Filed 2017·Application pending·0 cites
- 2459US6358308B2Finishing treatment of pigments in liquid or supercritical CO2CLARIANT GMBH·Filed 2000·Granted Mar 19, 2002·3 cites·8 claims
- 2559US2020241012A1RGMa Fragment Based Diagnostic AssayABBVIE DEUTSCHLAND·Filed 2019·Application pending·0 cites
- 2658US2017166633A1Antibodies against the rgm a protein and uses thereofABBVIE DEUTSCHLAND·Filed 2016·Application pending·0 cites
- 2757US6762299B2Mixed crystals of benzimidazolonedioxazine compoundsCLARIANT GMBH·Filed 2001·Granted Jul 13, 2004·3 cites·17 claims
- 2857US2025236795A1Liquid-crystalline mediumMERCK PATENT GMBH·Filed 2025·Application pending·0 cites
- 2956US10155770B2Substituted pyrazolopyrimidines and method of useABBVIE DEUTSCHLAND·Filed 2017·Granted Dec 18, 2018·0 cites·17 claims
- 3056US6620931B2Process for preparing new crystal polymorphs of a methyl-substituted benzimidazolone-dioxazine pigmentCLARIANT GMBH·Filed 2001·Granted Sep 16, 2003·3 cites·13 claims
- 3154US2011142845A1NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE NOGO-66 RECEPTOR (NgR) AND USES THEREOFABBOTT LAB·Filed 2010·Application pending·0 cites
- 3254US2017008959A1Ager-peptides and use thereofABBVIE DEUTSCHLAND·Filed 2016·Application pending·0 cites
- 3348US6191263B1Crystal modification of C.I. Pigment Red 53:2 (γ-phase)CLARIANT GMBH·Filed 1999·Granted Feb 20, 2001·4 cites·17 claims
- 3448US2017002075A1Antibodies to receptor of advanced glycation end products (rage) and uses thereofABBVIE DEUTSCHLAND·Filed 2016·Application pending·0 cites
- 3548US2016069907A1RGMa Fragment Based Diagnostic AssayABBVIE DEUTSCHLAND·Filed 2015·Application pending·0 cites
- 3646US2010322948A1Bone morphogenetic protein (BMP)-binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and use of sameABBOTT GMBH & CO KG·Filed 2008·Application pending·0 cites
- 3745US2017073353A1Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of useABBVIE INC·Filed 2016·Application pending·0 cites
- 3844US6228162B1Process for preparing new crystal modifications of C.I. pigment red 53:2CLARIANT GMBH·Filed 1999·Granted May 8, 2001·3 cites·11 claims
- 3944US6146455ACrystal modification of C.I. Pigment Red 53:2 (δ-phase)CLARIANT GMBH·Filed 1999·Granted Nov 14, 2000·3 cites·17 claims
- 4040US2008241722A1Mixed Crystals Comprising C.I. Pigment Red 170 DerivativesSCHMIDT MARTIN ULRICH·Filed 2004·Application pending·0 cites
- 4138US2022153822A1Means for specifically eliminating perilipin-1 fragment presenting adipocytesALYTAS THERAPEUTICS GMBH·Filed 2020·Application pending·0 cites
- 4236US6066502AEndothelin converting enzyme (ECE)BASF AG·Filed 1994·Granted May 23, 2000·2 cites·4 claims
- 4335US8877903B2Separation of insoluble target proteinsSCHMIDT MARTIN·Filed 2011·Granted Nov 4, 2014·0 cites·19 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →